Welcome to our dedicated page for Cullinan Therapeutics news (Ticker: CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Therapeutics stock.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a forward-thinking biopharmaceutical company dedicated to establishing new standards of care for patients through innovative cancer and autoimmune therapies. The company specializes in a modality-agnostic approach, targeting key drivers of disease and harnessing the immune system to eradicate diseased cells.
With a highly experienced team of oncology professionals and drug developers, Cullinan boasts a diversified portfolio of clinical-stage assets sourced from both internal and external collaborations. This includes therapies aimed at inhibiting disease drivers or activating the immune system to address various oncology and autoimmune indications.
Recent Achievements:
- CLN-617: A first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, shown to activate a broad immune response.
- CLN-619: A first-in-class monoclonal antibody for relapsed/refractory multiple myeloma, aimed at restoring immune recognition of tumor cells.
- CLN-978: A novel CD19xCD3 bispecific T cell engager being developed for systemic lupus erythematosus.
- Zipalertinib: An EGFR inhibitor for non-small cell lung cancer, with promising efficacy and a manageable safety profile.
Financially, Cullinan is well-positioned, having announced a $280 million private placement to support ongoing research and development activities. This funding, combined with current assets, is expected to sustain the company's operations into 2028.
For more detailed insights and updates, visit Cullinan’s website or follow them on LinkedIn and Twitter.
Cullinan Therapeutics has announced positive initial data from its Phase 2b REZILIENT1 study of zipalertinib for non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations. The study involves patients who progressed after amivantamab treatment, showing a 39% objective response rate (ORR) and a 94% disease control rate (DCR). The data, cut off as of January 12, 2024, reflects findings in 31 patients with a median of three prior treatments. Zipalertinib had a manageable safety profile, with no grade 4 or 5 treatment-related adverse events. The company remains on track to complete enrollment by the end of 2024 and retains a 50/50 profit share in the U.S. through its partnership with Taiho. An investor event will be held on June 1, 2024, to discuss this and other data.
Cullinan Therapeutics, a biopharmaceutical company focused on developing targeted therapies, has announced that its CEO, Nadim Ahmed, and CMO, Jeffrey Jones, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit.
The event, which will take place virtually on May 28 and 29, 2024, will feature their chat on May 29 at 11:30 am ET. A webcast of the event will be accessible on the company's investor relations website.
Cullinan Therapeutics announced preliminary data from its Phase 1 trial of CLN-619, an anti-MICA/B antibody, in combination with pembrolizumab, and updated monotherapy results. Among 22 patients treated with the combination, 3 showed partial responses, including in non-small cell lung cancer (NSCLC) and gastric cancer. Monotherapy results showed a 41.4% clinical benefit rate across various tumor types. CLN-619 was well tolerated, with most adverse events being mild. Cullinan is expanding the trial to include more NSCLC patients and has plans for further studies in multiple myeloma.
Cullinan Therapeutics (Nasdaq: CGEM) reported its Q1 2024 financial results and provided corporate updates. Key highlights include a strong cash position with $434.8 million in cash and investments as of March 31, 2024, and an additional $280 million from an April private placement, extending its cash runway into 2028. The company appointed David Meek to its Board of Directors. Research and development (R&D) expenses decreased to $30.6 million, while general and administrative (G&A) expenses increased to $12.3 million for the quarter. Cullinan reported a net loss of $37.3 million for Q1 2024, down from $58.1 million in Q1 2023. Significant clinical developments include presenting data for CLN-619 at the ASCO 2024 Annual Meeting and focusing CLN-978 on autoimmune diseases, beginning with systemic lupus erythematosus (SLE). The company aims to complete enrollment for the Phase 2b REZILIENT1 study by year-end 2024 and has multiple data catalysts expected through early 2025.
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) appoints Mary Kay Fenton as Chief Financial Officer, bringing three decades of experience in the biotechnology industry. Fenton will strengthen the company's financial and operational functions, aiming to accelerate growth and enhance shareholder value.
FAQ
What is the current stock price of Cullinan Therapeutics (CGEM)?
What is the market cap of Cullinan Therapeutics (CGEM)?
What does Cullinan Therapeutics, Inc. specialize in?
What is CLN-617?
What is the purpose of the recent $280 million private placement?
What is Zipalertinib?
What are the latest developments regarding CLN-619?
What types of diseases does Cullinan Therapeutics' portfolio address?
What is the strategic focus of Cullinan Therapeutics?
What is CLN-978 and its target indication?
How does Cullinan Therapeutics ensure the development of promising assets?
Where can I find more information about Cullinan Therapeutics?
